In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

The termination of certain employees and other actions under initiatives to outsource certain services per the firm's ongoing multi-year restructuring initiative will result in charges of about $5 mil.-$6 mil. before taxes, direct seller states in an Oct. 17 Securities and Exchange Commission filing. Charges of $4.4 mil. will be recorded in Q3 2006, firm says, adding the employee cuts will be completed by 2009. Avon announced its restructuring plan last fall, noting it will result in costs of $300 mil.-$500 mil. before taxes (1"The Rose Sheet" Nov. 21, 2005, p. 3)...

You may also be interested in...



Avon Restructuring Initiative Aimed At Restoring Growth

Avon will launch several new skin care and color cosmetics initiatives next year and significantly increase advertising investment in an effort to restore competitiveness and drive revenue growth, according to CEO Andrea Jung

Execs On The Move: BioVentrix Shuffles Board

Avalon Healthcare appoints two new directors; Lantheus Holdings appoints new chief accounting officer; and more.

UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

UsernamePublicRestriction

Register

RS014291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel